Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
-
Published:2023-12-15
Issue:3
Volume:12
Page:107-107
-
ISSN:2033-6403
-
Container-title:Generics and Biosimilars Initiative Journal
-
language:
-
Short-container-title:GaBI J
Abstract
A study by Meijboom et al. aimed to compare the risk of and reasons for infliximab discontinuation between retransitioned patients and those remaining on biosimilar [1].
Publisher
Pro Pharma Communications International